Adrian Wildfire
CEO CHIMagents, UK Tel: +44 (0)7770 862571 Email: adrian.wildfire@sgs.com
VALIDATE Role: Network Associate
Research Keywords: CHIM, URTIs (influenza / RSV), the hepatides Biography: Adrian Wildfire, Scientific Director, SGS Life Science Services, is a Master, Fellow and accredited specialist in the fields of Virology, Medical Microbiology and Parasitology. He is a subject matter expert in the controlled human infection modelling (CHIM) as a route to early efficacy data in clinical trials primarily for diseases of the upper and lower respiratory tract. Adrian started his career in 1987 as a Clinical Scientist, working with antimicrobial resistant isolates of tuberculosis under the tutelage of Professor Denis Mitchison within the Wolfson Research Institute (Royal Postgraduate Medical School), Hammersmith Hospital, London, UK (now part of the Imperial Group). This study was the first to examine the use of a combined therapy (Rifater) in multidrug resistant populations. Following this he transferred to the Medical Microbiology department within the Institute before going on to take his Fellowship at St. Mary’s Hospital. Becoming a Senior Medical Microbiologist, he worked in both the public and private sector assisting in setting up and later overseeing diagnostic services and research projects within clinical microbiology and virology laboratories. Adrian obtained a Parasitology Masters from the Royal Free Hospital and London School of Hygiene and Tropical Medicine shortly before moving to join Professor Brian Gazzard’s HIV Research team at the Chelsea and Westminster Hospital in 2001. Whilst there he worked primarily with HIV, Hepatitis and Sexual Health cohorts as well as sitting on various bodies as a subject matter expert (e.g. the Academic Health Science Centre, SAGE and the NHS Diagnostic Pathology Group). Latterly he obtained qualifications in Management as well as Project Management (PRINCE2) and Leadership (Harvard Leadership Program). Recently Adrian specialised in Controlled Human Infection Models as Director of Research Services at Retroscreen (hVIVO) before being head-hunted to head-up a multidisciplinary team within SGS Life Sciences manufacturing wild-type challenge agents for use in clinical trials, designing and performing CHIM and CHMIs and leading on infectious disease strategy and training. He has authored papers and articles relating to HIV, Ethics, Immunology and Human Challenge amongst others.
Related Websites:
Key Publications: Development and validation of a non-egg adapted wild-type influenza A H3N2 (A/Belgium/4217/2015 (H3N2)) with phenotypic characteristics of currently circulating strains as a challenge agent for human volunteer challenge studies. Schutten, M. Speder, B. Sheridan, J. Jeeninga, R. Vancleave, V. Lovatt, A. Stittelaar, K. and Wildfire, A. PLOS ONE, 2018 – under editorial review The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen. Waters, L. Mandalia, S. Randell, P. Wildfire, A. Gazzard, B. and Moyle, G. Clinical Infectious Diseases 46;10, 16171623, 2008 Genetic Diversity of Integrase (IN) Sequences in Antiretroviral Treatment-Naive and Treatment-Experienced HIV Type 2 Patients. L. Xu, J. Anderson, B. Ferns, P. Cook, A. Wildfire, J. Workman, S. Graham, E. Smit. AIDS Research and Human Retroviruses; 24(7): 1003-1007, 2008 Rights theory in a specific healthcare context: “Speaking ill of the dead”. Wildfire A, Stebbing J, Gazzard, B. Postgraduate Medical Journal 83; 473-477, 2007 Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. Moyle G, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard B. The Journal of Infectious Diseases 191; 866, 2005 The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors. Stebbing J, Bower M, Gazzard B, Wildfire A, Pandha H, Dalgleish A & Spicer J. Clinical and Experimental Immunology, 2004 Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Antimicrob Agents Chemother 48(7):2388-93, 2004 Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients. Stebbing J, Patterson S, Portsmouth S, Thomas C, Glassman R, Wildfire A, Gotch F, Bower M, Nelson M, Gazzard B. Cell Research 14(3): 251-256, 2004 Resolution of AIDS-related Castleman’s Disease with Anti-C Monoclonal Antibodies is Associated with Declining IL-6 and TNF-alpha Levels. Newsom-Davis T, Bower M, Wildfire A, Thirlwell C, Nelson M, Gazzard B, Stebbing J. Leukaemia and Lymphoma 45(9): 1939-1941, 2004 The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors. Stebbing J, Gazzard B, Kim L, Portsmouth S, Wildfire A, Teo I, Nelson M, Bower M, Gotch F, Shaunak S, Srivastava P, Patterson S. Blood 101(10): 4000-4004, 2003
|
